REVOLUTION MEDICINES INC (RVMD) Forecast, Price Target & Analyst Ratings
NASDAQ:RVMD • US76155X1000
98.4 USD
-1.24 (-1.24%)
At close: Mar 6, 2026
98.385 USD
-0.02 (-0.02%)
After Hours: 3/6/2026, 8:00:02 PM
View the latest analyst price targets, stock forecast, EPS estimates, revenue projections, revisions, full estimates, rating distribution and upgrades/downgrades for REVOLUTION MEDICINES INC (RVMD).
Forecast Snapshot
Consensus Price Target
$124.38
+ 26.40% Upside
Next Earnings Forecast
Release DateMay 5, 2026
PeriodQ1 / 2026
EPS Estimate-$1.80
Revenue Estimate4.206M
ChartMill Buy Consensus
87.41%
Weighted Analyst Rating Score
Price Target Details & History
Consensus Price Target and Range
Mean target
$124.38
Upside
+ 26.40%
From current price of $98.40 to mean target of $124.38, Based on 27 analyst forecasts
Low
$73.73
Median
$137.70
High
$178.50
Price Target Revisions
1 Month
34.00%
3 Months
53.03%
Price Target Summary
27 analysts have analysed RVMD and the average price target is 124.38 USD. This implies a price increase of 26.4% is expected in the next year compared to the current price of 98.4.
The average price target has been revised upward by 53.03% in the past 3 months.
Analyst Ratings & History
Current Analyst Ratings
Analyst Ratings History
Analyst Ratings Consensus
ChartMill Buy Consensus
87.41%
RVMD was analyzed by 27 analysts. The buy percentage consensus is at 87. So analysts seem to be very confident about RVMD.
In the previous month the buy percentage consensus was at a similar level.
RVMD was analyzed by 27 analysts, which is quite many. So the average rating should be quite meaningful.
Recent Upgrades & Downgrades
| Date | Firm | Action | From → To |
|---|---|---|---|
| 2026-02-26 | Needham | Maintains | Buy -> Buy |
| 2026-02-26 | Wells Fargo | Maintains | Overweight -> Overweight |
| 2026-02-26 | Piper Sandler | Maintains | Overweight -> Overweight |
| 2026-02-02 | JP Morgan | Maintains | Overweight -> Overweight |
| 2026-01-27 | Oppenheimer | Maintains | Outperform -> Outperform |
| 2026-01-22 | Stifel | Maintains | Buy -> Buy |
| 2026-01-21 | RBC Capital | Maintains | Outperform -> Outperform |
| 2026-01-20 | Guggenheim | Maintains | Buy -> Buy |
| 2026-01-13 | Mizuho | Maintains | Outperform -> Outperform |
| 2025-11-18 | Wolfe Research | Initiate | Outperform |
| 2025-11-06 | Needham | Maintains | Buy -> Buy |
| 2025-11-06 | Wedbush | Maintains | Outperform -> Outperform |
| 2025-11-06 | JP Morgan | Maintains | Overweight -> Overweight |
| 2025-11-06 | HC Wainwright & Co. | Maintains | Buy -> Buy |
| 2025-11-03 | RBC Capital | Initiate | Outperform |
| 2025-10-21 | Mizuho | Initiate | Outperform |
| 2025-10-17 | Wedbush | Reiterate | Outperform -> Outperform |
| 2025-10-17 | Raymond James | Maintains | Strong Buy -> Strong Buy |
| 2025-10-16 | Stifel | Reiterate | Buy |
| 2025-09-12 | Goldman Sachs | Maintains | Buy -> Buy |
| 2025-09-11 | Needham | Maintains | Buy -> Buy |
| 2025-09-11 | Wedbush | Maintains | Outperform -> Outperform |
| 2025-09-11 | Wells Fargo | Maintains | Overweight -> Overweight |
| 2025-09-05 | Truist Securities | Initiate | Buy |
| 2025-08-19 | Piper Sandler | Initiate | Overweight |
Next Earnings Forecast Details
Next Earnings Details
Release DateMay 5, 2026
PeriodQ1 / 2026
EPS Estimate-$1.80
Revenue Estimate4.206M
Revenue Q2QN/A
EPS Q2Q-59.69%
Number of Analysts17
Next Earnings Revisions
Revenue (1 Month)
6.24%
Revenue (3 Months)
34.31%
EPS (1 Month)
0.23%
EPS (3 Months)
1.73%
Next Earnings Summary
RVMD is expected to report earnings on 5/5/2026. The consensus EPS estimate for the next earnings is -1.8 USD and the consensus revenue estimate is 4.21M USD.
The next earnings revenue estimate has been revised upward by 34.31% in the past 3 months. Upward revisions are a positive sign and indicate that analysts are more optimistic about the next earnings compared to 3 months ago.
Full Analyst Estimates
Yearly Earnings Per Share (EPS), Revenue, EBIT, EBITDA and Operating Margin Analyst Estimates
| 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 | 2031 | 2032 | 2033 | ||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue YoY % growth | 29.39M -31.62% | 35.38M 20.38% | 11.58M -67.27% | 306K -100.00% | 4.502M | 48.013M | 266.4M 454.85% | 690.42M 159.17% | 2.18B 215.75% | 3.759B 72.43% | 5.318B 41.47% | 6.531B 22.81% | 8.033B 23.00% | |
| EBITDA YoY % growth | -183.86M -71.80% | -253.24M -37.74% | -481.075M -89.97% | -673.512M -41.74% | -1.153B -72.13% | -1.625B -38.45% | -1.477B 9.10% | -1.072B 27.46% | -368.832M 65.58% | 1.021B 376.82% | 2.675B 162.00% | 4.222B 57.83% | 5.826B 37.99% | |
| EBIT YoY % growth | -188.01M -69.84% | -258.28M -37.38% | -487.185M -88.63% | -680.641M -41.53% | -1.158B -71.48% | -1.307B -10.55% | -1.107B 15.32% | -746.075M 32.60% | 1.179M 100.16% | 1.297B 109,908.48% | 2.433B 87.59% | 3.601B 48.01% | 4.668B 29.63% | |
| Operating Margin | -639.71% | -730.02% | -4,207.12% | -222,431.83% | -25,730.04% | -2,722.46% | -415.52% | -108.06% | 0.05% | 34.50% | 45.75% | 55.14% | 58.11% | |
| EPS YoY % growth | -2.56 -19.63% | -3.10 -21.09% | -3.77 -21.71% | -3.54 5.38% | -5.70 -65.55% | -7.47 -26.40% | -6.48 13.31% | -5.02 22.53% | -0.11 97.83% | 6.17 5,765.98% | 9.98 61.85% | 15.12 51.51% | 20.16 33.29% |
All data in USD
Quarterly Earnings Per Share (EPS), Revenue, EBIT and EBITDA Analyst Estimates
| Q1 / 26 | Q2 / 26 | Q3 / 26 | Q4 / 26 | Q1 / 27 | Q2 / 27 | Q3 / 27 | Q4 / 27 | |
|---|---|---|---|---|---|---|---|---|
| EPS Q2Q % growth | -1.80 -59.69% | -1.81 -38.36% | -1.79 -11.37% | -1.73 7.12% | -1.58 12.38% | -1.51 16.71% | -1.44 19.79% | -1.36 21.47% |
| Revenue Q2Q % growth | 4.206M | 23.821M | 9.871M | 20.4M 385.02% | 40.8M 71.28% | 61.2M | 73.114M 640.69% | |
| EBITDA Q2Q % growth | -380.929M -64.00% | -400.891M -53.76% | -363.179M -17.55% | -361.223M -2.34% | -327.614M 14.00% | -311.498M 22.30% | -298.768M 17.74% | -288.344M 20.18% |
| EBIT Q2Q % growth | -364.775M -65.58% | -382.991M -44.68% | -352.316M -11.75% | -343.152M 5.11% | -328.858M 9.85% | -312.793M 18.33% | -296.82M 15.75% | -289.425M 15.66% |
All data in USD
Yearly Earnings Per Share (EPS) and Revenue Trends vs Historical Data
Long Term Forward Growth Forecast Summary
Long Term EPS Growth (CAGR)
EPS Next 3 Year
4.80%
EPS Next 5 Year
24.93%
Long Term Revenue Growth (CAGR)
Revenue Next 3 Year
435.27%
Revenue Next 5 Year
284.00%
Long Term EBIT Growth (CAGR)
EBIT Next 3 Year
2.44%
EBIT Next 5 Year
23.57%
REVOLUTION MEDICINES INC / RVMD Forecast FAQ
What is the average price target for REVOLUTION MEDICINES INC (RVMD) stock?
27 analysts have analysed RVMD and the average price target is 124.38 USD. This implies a price increase of 26.4% is expected in the next year compared to the current price of 98.4.
What is the next earnings date for RVMD stock?
REVOLUTION MEDICINES INC (RVMD) will report earnings on 2026-05-05, after the market close.
What are the consensus estimates for REVOLUTION MEDICINES INC (RVMD) next earnings?
The consensus EPS estimate for the next earnings of REVOLUTION MEDICINES INC (RVMD) is -1.8 USD and the consensus revenue estimate is 4.21M USD.
What is the expected long term growth rate for RVMD stock?
The expected long term growth rate for REVOLUTION MEDICINES INC (RVMD) is 435.27%.